Arginase-1: A Highly Specific Marker Separating Pancreatic Adenocarcinoma from Hepatocellular Carcinoma
Nazneen Fatima, Cynthia Cohen, Momin T Siddiqui. Emory University Hospital, Atlanta, GA
Background: The common developmental origin of the adult liver and pancreas has inspired investigation of the potential for hepatopancreatic precursor/stem cell persistence in liver and pancreas. Previous studies have demonstrated that Arginase-1 and HepPar-1 are effective immunohistochemical (IHC) markers for hepatocellular carcinoma (HCC). In this study we explored the possible efficacy of these stains in diagnosing pancreatic adenocarcinoma (PAD).
Design: Arginase-1 and HepPar-1 IHC was performed on formalin-fixed, paraffin-embedded fine needle aspiration (FNA) cell blocks (CB) of PAD (n=46), tissue microarray (TMA) of PAD (n=33), and FNA CB of HCC (n=44). Negative controls were also applied (PAD CB n=7, PAD TMA n=3, HCC CB n=35).
Results: PAD demonstrated Arginase-1 positivity in 0 of 46 cases and HepPar-1 positivity in 7 of 46 (15%) of CB's. PAD TMA demonstrated Arginase-1 positivity in 0 of 33 cases and HepPar-1 positivity in 4 of 33 (12%) of cases. HCC demonstrated Arginase-1 positivity in 37 of 44 (84%) cases and HepPar-1 positivity in 32 of 44 cases (72%).
|Arginase-1 (CB)||Arginase-1 (TMA)||HepPar-1 (CB)||HepPar-1 (TMA)|